Raleigh

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Asthma6 trials
• Type 2 diabetes4 trials
• Chronic kidney disease2 trials
• COPD2 trials
• Bladder cancer1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Liver cirrhosis1 trial
• Myasthenia gravis1 trial
• Obesity1 trial

Phase

• Phase 312 trials
• Phase 22 trials
• Phase 11 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed7 trials
• Recruiting6 trials
• Not yet recruiting2 trials
• Active, not recruiting1 trial
• Suspended1 trial

Lead sponsor

• AstraZeneca15 trials
• Alexion Pharmaceuticals, Inc.1 trial
• Daiichi Sankyo1 trial

Running trials

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· AstraZeneca· Source

• Recruiting

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· Phase 3· AstraZeneca· Source

• Recruiting

  Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

  NCT07610837· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

  NCT07221838· Phase 4· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

• Recruiting

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· Phase 2/3· Daiichi Sankyo· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes4 recruiting
• Chronic kidney disease2 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting
• Myasthenia gravis1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  A Study of Inhaled AZD8630 in Adolescents With Asthma

  NCT07065331· Phase 1· AstraZeneca· Source

• Completed

  A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

  NCT06644924· Phase 2· AstraZeneca· Source

• Completed

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· Phase 3· AstraZeneca· Source

• Completed

  A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

  NCT06075095· Phase 3· AstraZeneca· Source

• Completed

  A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

  NCT05755906· Phase 3· AstraZeneca· Source

• Completed

  A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

  NCT05202262· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· AstraZeneca· Source